Proceedings from a live event featuring traditional didactic faculty presentations and case-based panel discussions focused on all factors that influence multidisciplinary treatment decision-making for lung cancer. Featuring perspectives from Drs Jeffrey Bradley, Julie R Brahmer, Frank C Detterbeck, Ramaswamy Govindan, John Heymach, Bruce E Johnson, Rogerio C Lilenbaum, Thomas J Lynch Jr, Jyoti D Patel, Alice Shaw, Mark A Socinski and David R Spigel. (Video Program)
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists and other healthcare providers involved in the treatment of lung cancer.
OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease that accounts for more cancer-related deaths among both men and women than any other tumor type. Historically, systemic therapeutic options have been limited, but recent advances in our understanding of cellular and tumor biology have resulted in the development of numerous therapies demonstrating benefit in lung cancer. Despite these advances, many clinical scenarios continue to exist in which multiple treatment options may be available but the optimal strategy is highly debatable and may depend on rapidly evolving clinical research data. This unique educational activity delivers highly applicable current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Jeffrey Bradley, MD
S Lee Kling Professor of Radiation Oncology
Alvin J Siteman Cancer Center
Washington University School of Medicine
St Louis, Missouri
Paid Research: Varian Medical Systems Inc.
Julie R Brahmer, MD
Associate Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Merck; Paid Research: ArQule Inc, MedImmune Inc; Uncompensated Research: Bristol-Myers Squibb Company.
Frank C Detterbeck, MD
Professor and Chief, Section of Thoracic Surgery
Yale University School of Medicine
Director, Thoracic Oncology Program
Yale Cancer Center
Co-Director, Yale Lung Screening and Nodule Program
New Haven, Connecticut
Advisory Committee: Pfizer Inc; Speakers Bureau: Lilly USA LLC.
Ramaswamy Govindan, MD
Professor of Medicine
Co-Director, Section of Medical Oncology
Division of Oncology
Washington University School of Medicine
St Louis, Missouri
Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Covidien, Merck.
John Heymach, MD, PhD
Chief, Thoracic Medical Oncology
Associate Professor of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committee: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc; Consulting Agreements: OSI Oncology; Contracted Research: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Pfizer Inc.
Bruce E Johnson, MD
Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
ASCO Translational Research Professor
Boston, Massachusetts
Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Millennium: The Takeda Oncology Company, Pfizer Inc; Consulting Agreements: Chugai Pharmaceutical Co Ltd, Sanofi, Transgenomic Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genzyme Corporation, Millennium: The Takeda Oncology Company; Stock Ownership: KEW Group LLC.
Rogerio C Lilenbaum, MD
Chief Medical Officer
Smilow Cancer Hospital
Professor of Medicine
Yale University School of Medicine
New Haven, Connecticut
Consulting Agreement: Genentech BioOncology.
Thomas J Lynch Jr, MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven
Richard and Jonathan Sackler Professor of Internal Medicine
New Haven, Connecticut
Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck; Board of Directors: Infinity Pharmaceuticals Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck; Other Remunerated Activities: Partners HealthCare.
Jyoti D Patel, MD
Associate Professor of Medicine
Northwestern University
Feinberg School of Medicine
Division of Hematology/Oncology
Chicago, Illinois
Contracted Research: Lilly USA LLC.
Alice Shaw, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts
Advisory Committee and Consulting Agreements: ARIAD Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Novartis Pharmaceuticals Corporation, Pfizer Inc.
Mark A Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section
Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania
Contracted Research: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Pfizer Inc, Synta Pharmaceuticals Corp; Data and Safety Monitoring Board: Abbott Laboratories; Speakers Bureau: Celgene Corporation, Genentech BioOncology, Lilly USA LLC.
David R Spigel, MD
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology and Lilly USA LLC.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: May 2013
Expiration date: May 2014
Personalized Medicine in Lung Cancer: Ready for Prime Time? Bruce E Johnson, MD |
Introduction Neil Love, MD | |
Driver mutations in NSCLC Thomas J Lynch Jr, MD | |
Novel strategies for overcoming acquired resistance to EGFR TKIs Bruce E Johnson, MD | |
EML4-ALK and ROS1 translocations and crizotinib Alice Shaw, MD, PhD | |
Targeting MET in NSCLC Jyoti D Patel, MD | |
Faculty Case Discussion 1 |
First-line chemobiologic treatment of advanced PWT adenocarcinoma Jyoti D Patel, MD | |
Chemobiologic treatment of advanced squamous cell carcinoma of the lung Ramaswamy Govindan, MD | |
Available research data and potential integration of nab paclitaxel into the management of NSCLC Mark A Socinski, MD | |
Role of EGFR TKIs and monoclonal antibodies in the management of PWT adenocarcinoma Thomas J Lynch Jr, MD | |
Faculty Case Discussion 2 |
Critique of ongoing and maturing major cooperative group trials Mark A Socinski, MD |
Introduction Neil Love, MD | |
Adjuvant systemic treatment of NSCLC David R Spigel, MD | |
Controversies in the surgical management of lung cancer Frank C Detterbeck, MD | |
Multimodality treatment of locally advanced disease Jeffrey Bradley, MD | |
Management of lung cancer in the elderly and/or patients with poor performance status Rogerio C Lilenbaum, MD | |
Optimal staging of the mediastinum for patients with localized NSCLC Frank C Detterbeck, MD | |
Role of radiation therapy in localized and extensive small cell lung cancer Jeffrey Bradley, MD |
Immune tumor biology and related interventions Julie R Brahmer, MD | |
New agents and targets in NSCLC David R Spigel, MD | |
Next-generation VEGF and EGFR antibodies and multikinase inhibitors John Heymach, MD, PhD | |
Faculty Case Discussion 3 |
Predictions for 2014 Rogerio C Lilenbaum, MD |
(WIFI is recommended for best performance):